SuperworthLantheus EPS LNTH
Diluted earnings per share by quarter and over the last twelve months, from 2014.
- Last 12 months, to Jun 30, 2026
- $4.13
- Latest quarter, Q2 FY26
- $1.11
- −1% on a year earlier
- Fiscal year 2025
- $3.36
- −23% on the year before
Lantheus' earnings per share was $4.13 over the twelve months to Jun 30, 2026, up 10% on a year earlier.
In its latest quarter, Q2 FY26, it was $1.11, down 1% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $3.36 | −23% |
| FY2024 | $4.37 | −6% |
| FY2023 | $4.64 | +1265% |
| FY2022 | $0.34 | n/a |
| FY2021 | −$1.05 | n/a |
| FY2020 | −$0.23 | −129% |
| FY2019 | $0.79 | −24% |
| FY2018 | $1.04 | −67% |
| FY2017 | $3.19 | +280% |
| FY2016 | $0.84 | n/a |
| FY2015 | −$0.96 | n/a |
| FY2014 | −$0.20 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $1.11 | −1% | $4.13 | |
| Q1 FY26 | $1.80 | +76% | $4.14 | |
| Q4 FY25 | $0.81 | n/a | $3.36 | |
| Q3 FY25 | $0.41 | −77% | $2.38 | |
| Q2 FY25 | $1.12 | +27% | $3.76 | |
| Q1 FY25 | $1.02 | −45% | $3.52 | |
| Q4 FY24 | −$0.17 | −112% | $4.37 | |
| Q3 FY24 | $1.79 | −5% | $6.01 | |
| Q2 FY24 | $0.88 | −34% | $6.10 | |
| Q1 FY24 | $1.87 | n/a | $6.55 | |
| Q4 FY23 | $1.47 | n/a | $4.64 | |
| Q3 FY23 | $1.88 | +119% | $1.43 |
Against its peers
Companies in Medical - Diagnostics & Research nearest Lantheus' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| LNTHLantheus | $4.13 | +10% a year |
| BLLNBillionToOne | $0.65 | |
| CAICaris Life Sciences | $0.37 | |
| BIOBio-Rad Laboratories | $8.25 | −30% a year |
| VCYTVeracyte | $1.40 | +324% a year |
| CDNACareDx | $2.07 | +116% a year |
| RVTYRevvity | $2.10 | −11% a year |
| MEDPMedpace | $17.05 | +27% a year |
| LHLabcorp | $12.09 | +33% a year |
| DGXQuest Diagnostics | $9.41 | +18% a year |
| MTDMettler-Toledo International | $44.42 | +12% a year |
| Peer median | $5.17 |
Where Lantheus ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Lantheus
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.